A clinical trial to study the safety and efficacy of Ferumoxytol for the episodic treatment of Iron Deficiency Anemia
Phase 3
- Conditions
- Health Condition 1: null- The study population will consist of subjects who have completed study AMAG-FER-IDA-301
- Registration Number
- CTRI/2010/091/001462
- Lead Sponsor
- AMAG Pharmaceuticals Inc Sponsor
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 600
Inclusion Criteria
1. Subjects who have completed participation in study AMAG-FER-IDA-301
2. Female subjects of childbearing potential who are sexually active must be on an effective method of birth control and agree to remain on birth control until completion of participation in the study
Exclusion Criteria
1. Experienced an SAE related to ferumoxytol in study AMAG-FER-IDA-301
2. Female subjects who are pregnant, intend to become pregnant, are breastfeeding, or have a positive serum/urine pregnancy test
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method